Mycophenolate mofetil: Safety and efficacy in the prophylaxis of acute kidney transplantation rejection

Pranav Dalal, Monica Grafals, Darshika Chhabra, Lorenzo Gallon*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

17 Scopus citations

Abstract

Mycophenolate mofetil (MMF), a prodrug of mycophenolic acid (MPA), is an inhibitor of inosine monophosphate dehydrogenase (IMPDH). It preferentially inhibits denovo pathway of guanosine nucleotide synthesis in T and B-lymphocytes and prevents their proliferation, thereby suppresses both cell mediated and humoral immune responses. Clinical trials in kidney transplant recipients have shown the efficacy of MMF in reducing the incidence and severity of acute rejection episodes. It also improves long term graft function as well as graft and patient survival in kidney transplant recipients. MMF is useful as a component of toxicity sparing regimens to reduce or avoid exposure of steroids or calcineurin inhibitor (CNI). Enteric-coated mycophenolate sodium (EC-MPS) can be used as an alternative immunosuppressive agent in kidney transplant recipients with efficacy and safety profile similar to MMF.

Original languageEnglish (US)
Pages (from-to)139-149
Number of pages11
JournalTherapeutics and Clinical Risk Management
Volume5
Issue number1
StatePublished - Dec 1 2009

Keywords

  • Acute rejection
  • Kidney transplantation
  • Mycophenolate mofetil
  • Toxicity sparing

ASJC Scopus subject areas

  • Safety Research
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)
  • Chemical Health and Safety

Fingerprint Dive into the research topics of 'Mycophenolate mofetil: Safety and efficacy in the prophylaxis of acute kidney transplantation rejection'. Together they form a unique fingerprint.

Cite this